期刊文献+

阿托伐他汀钙不良反应与合理应用 被引量:5

Adverse reactions and clinical rational use of atorvastatin
下载PDF
导出
摘要 目的对常用药物阿托伐他汀钙所致的药品不良反应(ADR)进行调查分析,为临床应用提供参考。方法采用样本分析方法,收集2013年10月至2015年6月心血管内科服用阿托伐他汀钙的1 000份病历,统计分析患者年龄、性别、基础疾病、合并用药对ADR的影响。结果阿托伐他汀所致的ADR主要为肝转氨酶异常,占样本量的1.6%,50~70岁之间患者发生率高,男性多于女性,合并用药是导致ADR发生的危险因素之一。结论阿托伐他汀钙在应用过程中安全性高,ADR可控。 Objective To summarize the adverse reaction of atorvastatin and provide reference for its clinical application.Methods 1 000 cases from October 2013 to June 2015 in our hospital were selected.And the sample analysis method was used to analyze the influence of the age,gender,underlying diseases and the combined medication on ADR.Results The adverse reactions of atorvastatin were mainly liver damage,accounting for 1.6%,and higher in patients aged 50 ~ 70,men more than women,durg combination was one of the risk factors lead to ADR.Conclusion The safety of atorvastatin calcium is high,and the adverse reactions of liver damage is reversible,and could be widely used in clinic.
作者 白雪茜
出处 《吉林医药学院学报》 2016年第4期251-254,共4页 Journal of Jilin Medical University
关键词 阿托伐他汀 不良反应 样本分析 合理用药 atorvastatin adverse reaction sample analysis rational use of drug
  • 相关文献

参考文献14

二级参考文献61

  • 1李呐,邓海,夏小杰.他汀类药物与高血压[J].实用医技杂志,2004,11(07B):1303-1305. 被引量:7
  • 2康忠良,周立红.他汀类调脂药物的作用[J].检验医学与临床,2007,4(2):108-109. 被引量:1
  • 3李焱,甘小玲,刘珊英,陈庆瑜,黎锋,刘小珍.代谢综合征的临床特征及其危险因素分析[J].中国糖尿病杂志,2007,15(2):76-78. 被引量:10
  • 4中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5233
  • 5Martin PD,Dane AL,Nwose OM,et al. No effect of age or gender on the pharmaeokinetics of rosuvastatinta new HMG-CoA reduc- tase inhibitor[J]. J Clin Pharmacol,2002,42(10) : 1116-1121. 被引量:1
  • 6徐叔云,魏伟.临床药理学.3版.北京:人民卫生出版社,2005:173. 被引量:2
  • 7Lau WC, Waskell LA, Watkins PB. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation : a new drug - drug inter- action[ J]. Circulation,2003 ; 107:32 - 37. 被引量:1
  • 8Brophy JM, Babapulle MN, Costa V,et ul . A pharrnacoepidemiology study of the interaction between atorvastatin and dopidogrel after pereu- taneous coronary intervention [ J ]. Am Heart J,2006 ;152:263 - 269. 被引量:1
  • 9Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested [ J ]. Ciwulation,2003; 107:1568 - 1569. 被引量:1
  • 10Saw J, Steinhubl SR, Berger PB, etal. Lack of adverse elopidogrel- atorvastatin clinical interaction from secondary analysis of a randomized, placebo - controlled clopidogrel trial [ J ]. Circulation,2003 ; 108 : 921 - 924. 被引量:1

共引文献56

同被引文献32

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部